Broad Institute, Editas Medicine deal

Editas received exclusive, worldwide rights to Broad Institute’s IP related to CRISPR/ Cas9 gene editing system to develop human therapeutics. CRISPR systems use small guided RNAs that pair with a target DNA sequence and the Cas9 protein to excise target DNA. The Broad Institute said this technology has a wide range of therapeutic potential to treat diseases that require alteration in gene expression or mutation repair. The Broad Institute may license to third parties any genes Editas does not pursue. Editas was created in 2013 to develop the technology. ...